{
}
CRISPR technology is transforming genetic research and applications, with the global market projected to grow from USD 3.2 billion in 2023 to USD 15.0 billion by 2033, at a CAGR of 16.7%. North America leads in market share, driven by advancements in healthcare and agriculture, while ethical and regulatory challenges persist. The technology enhances crop resilience and supports biomedical research, paving the way for innovative therapies and sustainable agricultural practices.
Intellia Therapeutics is set to reduce its workforce by 27% as it aims for a commercial launch in 2027. This decision comes amid a trend of layoffs in the CRISPR sector, reflecting a growing reluctance from investors towards gene editing technologies.
Intellia Therapeutics, Inc. has seen its shares plummet 60.4% in 2024, significantly underperforming the industry and the S&P 500. Despite promising data from its CRISPR-based therapies, including the investigational nexiguran ziclumeran for ATTR amyloidosis, investor disappointment has grown due to recent trial results. The company continues to advance its innovative gene editing pipeline, with ongoing studies showing substantial serum TTR reduction in patients.
CRISPR Therapeutics, a pioneer in gene therapy, faces challenges despite its first FDA-approved CRISPR-based therapy, Casgevy. With shares down 46% from their peak and minimal revenue reported, the company must navigate intense competition and financial losses while aiming for future growth. Investors are advised to proceed with caution until sales momentum is evident.
Cathie Wood, CEO of Ark Invest, stated that her ARK Innovation fund, which has seen significant losses since its peak, should not constitute a large portion of any investment portfolio. She emphasized the fund's volatility and positioned it as a satellite strategy, while highlighting advancements in technologies like genome therapy that could drive future growth. Despite underperformance compared to the S&P 500, Wood remains confident in the fund's unique approach and potential.
Intellia Therapeutics reported mixed Phase 2 results for its CRISPR-based therapy NTLA-2002, aimed at treating hereditary angioedema. The study showed a 75% to 77% reduction in attacks among patients, with some remaining attack-free for months post-treatment. Despite a 20% drop in shares, experts highlight the therapy's potential as a one-time curative option, contrasting it with traditional treatments.
Intellia Therapeutics, Inc.
Companies
| Symbol | NTLA |
| Name | Intellia Therapeutics, Inc. |
| Currency | USD |
| Sector | Health Care |
| IndustryGroup | Pharmaceuticals, Biotechnology & Life Sciences |
| Industry | Biotechnology |
| Market | NASDAQ Global Select |
| Country | United States |
| State | MA |
| City | Cambridge |
| Zipcode | 2139 |
| Website | http://www.intelliatx.com |
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
CRISPR technology market poised for rapid growth and transformative advancements
Euro
United States Dollar
Editas Medicine, Inc.
CRISPR Therapeutics AG
Intellia Therapeutics, Inc.
USA
Show more
13:04 14.01.2025
Intellia therapeutics announces 27 percent workforce reduction ahead of 2027 launch
02:22 10.01.2025
Intellia Therapeutics stock plummets amid disappointing therapy data and performance
18:57 20.12.2024
crisper therapeutics faces challenges despite first mover advantage in gene therapy
United States Dollar
Intellia Therapeutics, Inc.
Beam Therapeutics Inc.
CRISPR Therapeutics AG
Vertex Pharmaceuticals Inc
CHE
Dan Victor
Show more
16:32 14.12.2024
cathie wood advises caution with ark innovation fund amid underperformance
15:55 15.11.2024
intellia's gene editing therapy shows promise for hereditary angioedema treatment
Intellia Therapeutics, Inc.
Verve Therapeutics, Inc.
Mount Sinai Properties Inc.
USA
Kiran Musunuru
Paula Busse
Show more
17:17 24.10.2024
Trending
Subcategory
Corporate News
Industry Trends
Startups & Entrepreneurship
Global Trade Developments
Government Economic Policies
Retail and Consumer Goods
Supply Chain Management
Industry Mergers & Acquisitions
Stock Market Updates
Energy Sector Developments
Venture Capital Investments
Global Financial Events
Finance Mergers & Acquisitions
Central Bank Actions
Cryptocurrency & Blockchain Regulations
Emerging Startups
Inflation and Monetary Impact
Private Equity Deals
Funding Rounds & Investments
Market Analysis and Predictions
Countries:
Companies:
Apple Inc.
NVIDIA Corporation
Google Inc.
Dell Technologies Inc.
Samsung Securities Co.,Ltd.
Learning Resources Inc.
MGA Entertainment Inc.
XPeng Inc.
Toyota Motor Corp
State Street Global Advisors Luxembourg SICAV - SSGA EMU ESG Screened Equity Fund
European Union Bonds
Taiwan Semiconductor Manufacturing Company Limited
Microsoft Corporation
Verizon Communications Inc.
SLB 4,6% 01JUN25
Equinor Ventures AS
Quanta Services, Inc.
Gold Circuit Electronics Ltd.
Unimicron Technology Corp.
Yatra Online, Inc.
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Japanese Yen
Australian Dollar
United Arab Emirates Dirham
British Pound Sterling
New Taiwan Dollar
New Zealand Dollar
Vietnamese Đồng
South Korean Won
Egyptian Pound
Thai Baht
Saudi Riyal
Indonesian Rupiah
South African Rand
Malaysian Ringgit
Singapore Dollar
Lebanese Pound
People: